UK Markets close in 3 hrs 54 mins

Hikma Pharmaceuticals PLC (HIK.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
2,579.00-55.00 (-2.09%)
As of 12:20PM GMT. Market open.

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees8,600

Key executives

NameTitlePayExercisedYear born
Mr. Said Samih Taleb DarwazahExec. Chairman3.05MN/A1957
Mr. Sigurdur Oli Olafsson Ph.D.CEO & Exec. Director4.12MN/A1969
Mr. Mazen Samih Taleb DarwazahExec. Vice Chairman & Pres of MENA2.18MN/A1958
Mr. Khalid Waleed Hosny Al NabilsiChief Financial OfficerN/AN/A1972
Dr. Shahin FesharakiChief Scientific Officer & Global Head of Research Devel.N/AN/AN/A
Mr. Hussein ArkhaghaChief CounselN/AN/AN/A
Mr. Bassam Wael Rushdi KanaanExec. VP of Corp. Devel. and M&AN/AN/A1965
Ms. Susan RingdalExec. VP of Strategic Planning & Global AffairsN/AN/AN/A
Ms. Majda LabadiExec. VP of Organisational Devel.N/AN/AN/A
Mr. Riad MishlawiPres of InjectablesN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops and manufactures oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Corporate governance

Hikma Pharmaceuticals PLC’s ISS governance QualityScore as of 1 November 2019 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.